The impact of PSA screening on prostate cancer mortality and overdiagnosis of prostate cancer in the United States

Journals of Gerontology - Series A Biological Sciences and Medical Sciences

Volumn 68, Issue 1, 2013, Pages 56-61

  Howrey, Bret T ^a,b   Kuo, Yong Fang ^b,c   Lin, Yu Li ^b   Goodwin, James S ^b,c  

^a Department of Family Medicine ^*  (United States)

^b Sealy Center on Aging   (United States)

^c UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

Cancer deaths; Health disparities; Medicare; PSA screening

Indexed keywords

KALLIKREIN; KALLIKREIN RELATED PEPTIDASE 3, HUMAN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN; PROSTATE SPECIFIC ANTIGEN;

AFRICAN AMERICAN; AGED; ARTICLE; BIOPSY; BLOOD; CAUCASIAN; COHORT ANALYSIS; HEALTH CARE DISPARITY; HUMAN; MALE; MASS SCREENING; MEDICARE; MORTALITY; PROSTATE TUMOR; STATISTICS; UNITED STATES; UTILIZATION REVIEW;

AFRICAN AMERICANS; AGED; BIOPSY; COHORT STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; HEALTHCARE DISPARITIES; HUMANS; KALLIKREINS; MALE; MASS SCREENING; MEDICARE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; UNITED STATES;

EID: 84871908883     PISSN: 10795006     EISSN: 1758535X     Source Type: Journal    
DOI: 10.1093/gerona/gls135     Document Type: Article

References (36)

1. Welch HG, Albertsen PC. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst. 2009;101:1325-1329.
2. Kilpelainen TP, Tammela TL, Maattanen L, et al. False-positive screening results in the Finnish prostate cancer screening trial. Br J Cancer. 2010;102:469-474.
3. Vickers AJ, Cronin AM, Bjork T, et al. Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. BMJ. 2010;341:c4521. doi: 10.1136/bmj.c4521.
4. Concato J, Wells CK, Horwitz RI, et al. The effectiveness of screening for prostate cancer: a nested case-control study. Arch Intern Med. 2006;166:38-43.
5. Lu-Yao G, Albertsen PC, Stanford JL, Stukel TA, Walker-Corkery E, Barry MJ. Screening, treatment, and prostate cancer mortality in the Seattle area and Connecticut: fifteen-year follow-up. J Gen Intern Med. 2008;23:1809-1814.
6. Stattin P, Holmberg E, Johansson JE, Holmberg L, Adolfsson J, Hugosson J. Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study. J Natl Cancer Inst. 2010; 102:950-958.
7. Hugosson J, Carlsson S, Aus G, et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol. 2010;11:725-732.
8. Ilic D, O'Connor D, Green S, Wilt T. Screening for prostate cancer: a Cochrane systematic review. Cancer Causes Control. 2007;18: 279-285.
9. Djulbegovic M, Beyth RJ, Neuberger MM, et al. Screening for prostate cancer: systematic review and meta-analysis of randomized controlled trials. BMJ. 2010;341:c4543. doi: 10.1136/bmj.c4543.
10. Etzioni R, Penson DF, Legler JM, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst. 2002;94:981-990.
11. Brawley OW. Prostate cancer screening: is this a teachable moment? J Natl Cancer Inst. 2009;101:1295-1297.
12. Draisma G, Etzioni R, Tsodikov A, et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst. 2009;101:374-383.
13. Ketchandji M, Kuo YF, Shahinian VB, Goodwin JS. Cause of death in older men after diagnosis of prostate cancer. J Am Geriatr Soc. 2008; 57:24-30.
14. Andriole GL, Crawford ED, Grubb RL, et al. Mortality results from a randomized prostate-cancer screening trial. N Eng J Med. 2009;360: 1310-1319.
15. Andriole GL, Crawford ED, Grubb RL, et al. Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012;104:125-132.
16. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320-1328.
17. Schroder FH, Hugosson J, Roobol MJ, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med. 2012;366:981-990.
18. Lu-Yao G, Albertsen PC, Stanford JL, Stukel TA, Walker-Corkery ES, Barry MJ. Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. BMJ. 2002;325:740-745.
19. Shibata A, Ma J, Whittemore AS. Prostate cancer incidence and mortality in the United States and the United Kingdom. J Natl Cancer Inst. 1998;90:1230-1231.
20. Crocetti E, Ciatto S, Zappa M. Prostate cancer: different incidence but not mortality trends within two areas of Tuscany, Italy. J Natl Cancer Instit. 2001;93:876-877.
21. Schwartz G, Hanchette C. UV, latitude, and spatial trends in prostate cancer mortality: all sunlight is not the same (United States). Cancer Causes Control. 2006;17:1091-1101.
22. Bray F. Age-standardization. In: Parkin D, Whelan S, Ferlay J et al., eds. Cancer Incidence in Five Continents. Lyon, France: International Agency for Research on Cancer; 2002:87-89.
23. Selvin S. Epidemiologic Analysis: A Case-oriented Approach. New York, NY: Oxford University Press; 2001.
24. Wolf AMD, Wender RC, Etzioni RB, et al. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin. 2010;60:70-98.
25. Miller DC, Hollenbeck BK. Missing the mark on prostate-specific antigen screening. JAMA. 2011;306(24):2719-2720.
26. Volk RJ, Wolf A. Grading the new US preventive services task force prostate cancer screening recommendation. JAMA. 2011;306(24): 2715-2716.
27. Zeliadt SB, Hoffman RM, Etzioni R, Gore JL, Kessler LG, Lin D W. Influence of publication of US and European prostate cancer screening trials on PSA testing practices. J Natl Cancer Inst. 2011;103:520-523.
28. Bynum J, Song Y, Fisher E. Variation in prostate-specific antigen screening in men aged 80 and older in fee-for-service Medicare. J Am Geriatr Soc. 2010;58:674-680.
29. Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer. 2005;103:1615-1624.
30. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Determinants of androgen deprivation use for prostate cancer: role of the urologist. J Natl Cancer Instit. 2006;98:839-845.
31. Kuo YF, Shahinian VB, Goodwin JS. Gonadotropin-releasing hormone agonist use in men without cancer registry diagnoses of prostate cancer. BMC Health Serv Res. 2008;8:146.
32. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Eng J Med. 2005;352: 154-164.
33. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of the " Androgen Deprivation Syndrome " in men receiving androgen deprivation for prostate cancer. Arch Intern Med. 2006;166:465-471.
34. Percy C, Stanek E, Gloeckler L. Accuracy of cancer deaths certificates and its effect on cancer mortality statistics. Am J Pub Health. 1981;71: 242-250.
35. Albertsen P, Walters S, Hanley J. A comparison of cause of death determination in men previously diagnosed with prostate cancer who died in 1985 or 1995. J Urol. 2000;163:519-523.
36. Penson DF, Albertsen PC, Nelson PS, Barry M, Stanford JL. Determining cause of death in prostate cancer: are death certificates valid? J Natl Cancer Inst. 2001;93:1822-1823.